Ichihara Eiki, Kiura Katsuyuki, Tanimoto Mitsune
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Acta Med Okayama. 2011 Dec;65(6):353-62. doi: 10.18926/AMO/47260.
Angiogenesis is an essential process in tumor growth. The concept of angiogenesis, when proposed by Folksman in 1971, had a great impact on cancer research and therapy, as the survival and proliferation of cancer depend on angiogenesis, which could be a target of cancer therapy. In subsequent decades, numerous antiangiogenic agents were developed, and some of them have been applied clinically. However, angiogenesis includes a complex and multistep process that has not been sufficiently elucidated. In this review, we focus on signaling pathways related with tumor angiogenesis and several antiangiogenic agents approved by the United States Food and Drug Administration or under investigation.
血管生成是肿瘤生长过程中的一个重要过程。1971年，福克曼提出血管生成的概念，这对癌症研究和治疗产生了重大影响，因为癌症的存活和增殖依赖于血管生成，而血管生成可能成为癌症治疗的靶点。在随后的几十年里，人们开发了许多抗血管生成药物，其中一些已应用于临床。然而，血管生成是一个复杂的多步骤过程，尚未得到充分阐明。在本综述中，我们重点关注与肿瘤血管生成相关的信号通路以及美国食品药品监督管理局批准或正在研究的几种抗血管生成药物。
